These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Challenges in evaluating post-licensure vaccine safety: observations from the Centers for Disease Control and Prevention. Moro PL; Haber P; McNeil MM Expert Rev Vaccines; 2019 Oct; 18(10):1091-1101. PubMed ID: 31580725 [No Abstract] [Full Text] [Related]
5. Challenges in the development, licensure, and use of combination vaccines. Postema AS; Myers MG; Breiman RF Clin Infect Dis; 2001 Dec; 33 Suppl 4():S261-6. PubMed ID: 11709757 [TBL] [Abstract][Full Text] [Related]
6. Combination vaccines. Decker MD Prim Care; 2001 Dec; 28(4):739-61, vi. PubMed ID: 11739028 [TBL] [Abstract][Full Text] [Related]
7. Adjuvant Systems for vaccines: 13 years of post-licensure experience in diverse populations have progressed the way adjuvanted vaccine safety is investigated and understood. Laupèze B; Hervé C; Di Pasquale A; Tavares Da Silva F Vaccine; 2019 Sep; 37(38):5670-5680. PubMed ID: 31420171 [TBL] [Abstract][Full Text] [Related]
8. Current regional consensus recommendations on infant vaccination of the Latin American pediatric infectious diseases society (SLIPE). Falleiros-Arlant LH; Torres JR; Lopez E; Avila-Agüero ML; Ulloa-Gutierrez R; Mascareñas A; Brea J Expert Rev Vaccines; 2020 Jun; 19(6):491-498. PubMed ID: 32580593 [TBL] [Abstract][Full Text] [Related]
9. Post-authorization safety surveillance of a liquid pentavalent vaccine in Guatemalan children. Asturias EJ; Contreras-Roldan IL; Ram M; Garcia-Melgar AJ; Morales-Oquendo V; Hartman K; Rauscher M; Moulton LH; Halsey NA Vaccine; 2013 Dec; 31(49):5909-14. PubMed ID: 24055354 [TBL] [Abstract][Full Text] [Related]
10. Continuous active surveillance of adverse events following immunisation using SMS technology. Westphal DW; Williams SA; Leeb A; Effler PV Vaccine; 2016 Jun; 34(29):3350-5. PubMed ID: 27206385 [TBL] [Abstract][Full Text] [Related]
11. Simultaneous vaccination of Chinese applicants for a United States immigrant visa. Hua L; Hongtao H; Shunqin W; Jinping G; Jiandong C; Zhaoliang L; Xinwen F Travel Med Infect Dis; 2008 May; 6(3):130-6. PubMed ID: 18486068 [TBL] [Abstract][Full Text] [Related]
12. Latin American forum on immunization services during the COVID-19 pandemic. Ávila-Agüero ML; Ospina-Henao S; Pirez MC; Gentile Á; Araya S; Brea J; Mendoza L; Falleiros-Arlant LH Expert Rev Vaccines; 2021 Mar; 20(3):231-234. PubMed ID: 33554682 [No Abstract] [Full Text] [Related]
13. Pediatric anaphylactic adverse events following immunization in Victoria, Australia from 2007 to 2013. Cheng DR; Perrett KP; Choo S; Danchin M; Buttery JP; Crawford NW Vaccine; 2015 Mar; 33(13):1602-7. PubMed ID: 25698493 [TBL] [Abstract][Full Text] [Related]
14. Immunization of preterm infants with GSK's hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: A review of safety and immunogenicity. Omeñaca F; Vázquez L; Garcia-Corbeira P; Mesaros N; Hanssens L; Dolhain J; Gómez IP; Liese J; Knuf M Vaccine; 2018 Feb; 36(7):986-996. PubMed ID: 29336924 [TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: a randomized trial in the United States. Klein NP; Abu-Elyazeed R; Cheuvart B; Janssens W; Mesaros N Hum Vaccin Immunother; 2019; 15(4):809-821. PubMed ID: 30444673 [TBL] [Abstract][Full Text] [Related]
17. Safety of human papillomavirus vaccines: a review. Stillo M; Carrillo Santisteve P; Lopalco PL Expert Opin Drug Saf; 2015 May; 14(5):697-712. PubMed ID: 25689872 [TBL] [Abstract][Full Text] [Related]
18. Infant vaccine co-administration: review of 18 years of experience with GSK's hexavalent vaccine co-administered with routine childhood vaccines. Dolhain J; Janssens W; Dindore V; Mihalyi A Expert Rev Vaccines; 2020 May; 19(5):419-443. PubMed ID: 32419537 [TBL] [Abstract][Full Text] [Related]
19. The complementary roles of Phase 3 trials and post-licensure surveillance in the evaluation of new vaccines. Lopalco PL; DeStefano F Vaccine; 2015 Mar; 33(13):1541-8. PubMed ID: 25444788 [TBL] [Abstract][Full Text] [Related]
20. Surveillance of adverse events following the introduction of 13-valent pneumococcal conjugate vaccine in infants, and comparison with adverse events following 7-valent pneumococcal conjugate vaccine, in Victoria, Australia. Littlejohn ES; Clothier HJ; Perrett KP; Danchin M Hum Vaccin Immunother; 2015; 11(7):1828-35. PubMed ID: 26075435 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]